Changes in the nutrient quality of meat in an obesity context.

H. Schönfeldt,N. Gibson

DOI: https://doi.org/10.1016/j.meatsci.2008.05.025

IF: 7.077

2008-09-01

Meat Science

Abstract:

What problem does this paper attempt to address?

Assessing Breast Cancer Volume Alterations Post-Neoadjuvant Chemotherapy Through DenseNet-201 Deep Learning Analysis on DCE-MRI

Zhenqi Gu,Jing Huang,Changyu Zhou,Qi Wang,Jianchun Kong,Xiongbin You,Ziwei Zhang,Hong Zhao

DOI: https://doi.org/10.1016/j.jrras.2024.100971

IF: 1.77

2024-01-01

Journal of Radiation Research and Applied Sciences

Abstract:BackgroundChanges in tumor volume following neoadjuvant chemotherapy (NAC) are a crucial reference for determining surgical approaches in breast cancer, especially important for patients desiring breast conservation.MethodsBetween September 2015 and July 2022, 118 breast cancer cases from 109 patients were retrospectively gathered and randomly split into two cohorts: a training cohort of 83 cases and a test cohort of 35 cases. Deep learning models with DenseNet-201 architecture were constructed based on the peak enhanced phase of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Deep learning models were created to identify breast cancers that would experience tumor/node (T/N) stage downstaging or more than 90% reduction in MRI volume post-NAC. Their performance was compared with clinical models using receiver operator characteristic (ROC) curves for evaluation. The DeLong's test was used to determine significant differences in AUC among different models.ResultsIn the evaluation on a test cohort, a deep learning model showcased significantly better accuracy in predicting the downstaging of T/N stages in breast cancer with an AUC of 0.85. This performance markedly exceeded that of the traditional clinical model, which achieved an AUC of only 0.44. The deep learning model also excelled in predicting cases of breast cancer with more than 90% reduction in MRI volume, achieving an AUC of 0.89. This was superior to the clinical model's performance, which had an AUC of 0.61. The DeLong's test results showed that the predictive performance of the deep learning models was significantly better than that of the clinical models (P both <0.05).ConclusionThe deep learning model developed using DCE-MRI can accurately predict a tumor volume reduction of over 90% and downstaging of T/N stages in breast cancer patients after NAC, thereby potentially facilitating personalized treatment planning.
Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset

Richard Ha,Christine Chin,Jenika Karcich,Michael Z Liu,Peter Chang,Simukayi Mutasa,Eduardo Pascual Van Sant,Ralph T Wynn,Eileen Connolly,Sachin Jambawalikar

DOI: https://doi.org/10.1007/s10278-018-0144-1

Abstract:We hypothesize that convolutional neural networks (CNN) can be used to predict neoadjuvant chemotherapy (NAC) response using a breast MRI tumor dataset prior to initiation of chemotherapy. An institutional review board-approved retrospective review of our database from January 2009 to June 2016 identified 141 locally advanced breast cancer patients who (1) underwent breast MRI prior to the initiation of NAC, (2) successfully completed adriamycin/taxane-based NAC, and (3) underwent surgical resection with available final surgical pathology data. Patients were classified into three groups based on their NAC response confirmed on final surgical pathology: complete (group 1), partial (group 2), and no response/progression (group 3). A total of 3107 volumetric slices of 141 tumors were evaluated. Breast tumor was identified on first T1 postcontrast dynamic images and underwent 3D segmentation. CNN consisted of ten convolutional layers, four max-pooling layers, and dropout of 50% after a fully connected layer. Dropout, augmentation, and L2 regularization were implemented to prevent overfitting of data. Non-linear functions were modeled by a rectified linear unit (ReLU). Batch normalization was used between the convolutional and ReLU layers to limit drift of layer activations during training. A three-class neoadjuvant prediction model was evaluated (group 1, group 2, or group 3). The CNN achieved an overall accuracy of 88% in three-class prediction of neoadjuvant treatment response. Three-class prediction discriminating one group from the other two was analyzed. Group 1 had a specificity of 95.1% ± 3.1%, sensitivity of 73.9% ± 4.5%, and accuracy of 87.7% ± 0.6%. Group 2 (partial response) had a specificity of 91.6% ± 1.3%, sensitivity of 82.4% ± 2.7%, and accuracy of 87.7% ± 0.6%. Group 3 (no response/progression) had a specificity of 93.4% ± 2.9%, sensitivity of 76.8% ± 5.7%, and accuracy of 87.8% ± 0.6%. It is feasible for current deep CNN architectures to be trained to predict NAC treatment response using a breast MRI dataset obtained prior to initiation of chemotherapy. Larger dataset will likely improve our prediction model.
Deep learning-based prediction of response to HER2-targeted neoadjuvant chemotherapy from pre-treatment dynamic breast MRI: A multi-institutional validation study

Nathaniel Braman,Mohammed El Adoui,Manasa Vulchi,Paulette Turk,Maryam Etesami,Pingfu Fu,Kaustav Bera,Stylianos Drisis,Vinay Varadan,Donna Plecha,Mohammed Benjelloun,Jame Abraham,Anant Madabhushi

DOI: https://doi.org/10.48550/arXiv.2001.08570

2020-01-22

Quantitative Methods

Abstract:Predicting response to neoadjuvant therapy is a vexing challenge in breast cancer. In this study, we evaluate the ability of deep learning to predict response to HER2-targeted neo-adjuvant chemotherapy (NAC) from pre-treatment dynamic contrast-enhanced (DCE) MRI acquired prior to treatment. In a retrospective study encompassing DCE-MRI data from a total of 157 HER2+ breast cancer patients from 5 institutions, we developed and validated a deep learning approach for predicting pathological complete response (pCR) to HER2-targeted NAC prior to treatment. 100 patients who received HER2-targeted neoadjuvant chemotherapy at a single institution were used to train (n=85) and tune (n=15) a convolutional neural network (CNN) to predict pCR. A multi-input CNN leveraging both pre-contrast and late post-contrast DCE-MRI acquisitions was identified to achieve optimal response prediction within the validation set (AUC=0.93). This model was then tested on two independent testing cohorts with pre-treatment DCE-MRI data. It achieved strong performance in a 28 patient testing set from a second institution (AUC=0.85, 95% CI 0.67-1.0, p=.0008) and a 29 patient multicenter trial including data from 3 additional institutions (AUC=0.77, 95% CI 0.58-0.97, p=0.006). Deep learning-based response prediction model was found to exceed a multivariable model incorporating predictive clinical variables (AUC < .65 in testing cohorts) and a model of semi-quantitative DCE-MRI pharmacokinetic measurements (AUC < .60 in testing cohorts). The results presented in this work across multiple sites suggest that with further validation deep learning could provide an effective and reliable tool to guide targeted therapy in breast cancer, thus reducing overtreatment among HER2+ patients.
Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy

Maria Colomba Comes,Annarita Fanizzi,Samantha Bove,Vittorio Didonna,Sergio Diotiaiuti,Federico Fadda,Daniele La Forgia,Francesco Giotta,Agnese Latorre,Annalisa Nardone,Gennaro Palmiotti,Cosmo Maurizio Ressa,Lucia Rinaldi,Alessandro Rizzo,Tiziana Talienti,Pasquale Tamborra,Alfredo Zito,Vito Lorusso,Raffaella Massafra

DOI: https://doi.org/10.1016/j.compbiomed.2024.108132

Abstract:Background: So far, baseline Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) has played a key role for the application of sophisticated artificial intelligence-based models using Convolutional Neural Networks (CNNs) to extract quantitative imaging information as earlier indicators of pathological Complete Response (pCR) achievement in breast cancer patients treated with neoadjuvant chemotherapy (NAC). However, these models did not exploit the DCE-MRI exams in their full geometry as 3D volume but analysed only few individual slices independently, thus neglecting the depth information. Method: This study aimed to develop an explainable 3D CNN, which fulfilled the task of pCR prediction before the beginning of NAC, by leveraging the 3D information of post-contrast baseline breast DCE-MRI exams. Specifically, for each patient, the network took in input a 3D sequence containing the tumor region, which was previously automatically identified along the DCE-MRI exam. A visual explanation of the decision-making process of the network was also provided. Results: To the best of our knowledge, our proposal is competitive than other models in the field, which made use of imaging data alone, reaching a median AUC value of 81.8%, 95%CI [75.3%; 88.3%], a median accuracy value of 78.7%, 95%CI [74.8%; 82.5%], a median sensitivity value of 69.8%, 95%CI [59.6%; 79.9%] and a median specificity value of 83.3%, 95%CI [82.6%; 84.0%], respectively. The median and CIs were computed according to a 10-fold cross-validation scheme for 5 rounds. Conclusion: Finally, this proposal holds high potential to support clinicians on non-invasively early pursuing or changing patient-centric NAC pathways.
Deep Learning Model Based on Dual-Modal Ultrasound and Molecular Data for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer

Jia-Xin Huang,Jun Shi,Sai-Sai Ding,Hui-Li Zhang,Xue-Yan Wang,Shi-Yang Lin,Yan-Fen Xu,Ming-Jie Wei,Long-Zhong Liu,Xiao-Qing Pei

DOI: https://doi.org/10.1016/j.acra.2023.03.036

IF: 5.482

2023-06-03

Academic Radiology

Abstract:Rationale and Objectives To carry out radiomics analysis/deep convolutional neural network (CNN) based on B-mode ultrasound (BUS) and shear wave elastography (SWE) to predict response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Materials and Methods In this prospective study, 255 breast cancer patients who received NAC between September 2016 and December 2021 were included. Radiomics models were designed using a support vector machine classifier based on US images obtained before treatment, including BUS and SWE. And CNN models also were developed using ResNet architecture. The final predictive model was developed by combining the dual-modal US and independently associated clinicopathologic characteristics. The predictive performances of the models were assessed with five-fold cross-validation. Results Pretreatment SWE performed better than BUS in predicting the response to NAC for breast cancer for both the CNN and radiomics models ( P < 0.001). The predictive results of the CNN models were significantly better than the radiomics models, with AUCs of 0.72 versus 0.69 for BUS and 0.80 versus 0.77 for SWE, respectively ( P = 0.003). The CNN model based on the dual-modal US and molecular data exhibited outstanding performance in predicting NAC response, with an accuracy of 83.60% ± 2.63%, a sensitivity of 87.76% ± 6.44%, and a specificity of 77.45% ± 4.38%. Conclusion The pretreatment CNN model based on the dual-modal US and molecular data achieved excellent performance for predicting the response to chemotherapy in breast cancer. Therefore, this model has the potential to serve as a non-invasive objective biomarker to predict NAC response and aid clinicians with individual treatments.

radiology, nuclear medicine & medical imaging
A Novel Machine Learning Approach for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: Integration of Multimodal Radiomics With Clinical and Molecular Subtype Markers

Samir Elmougy,Norah Saleh Alghamdi,Amal AbouEleneen,S. Shamaa,Abdelrahman Gamal,S. Contractor,M. Ghazal,A. El-Baz,Khadiga M. Ali,A. Sharafeldeen,Ahmed Elsaid Tolba,Reham Alghandour,Eman Alnaghy

DOI: https://doi.org/10.1109/ACCESS.2024.3432459

IF: 3.9

IEEE Access

Abstract:The primary objective of this paper is to develop a machine learning-based approach capable of predicting the treatment response of neoadjuvant chemotherapy (NAC) to enhance breast cancer treatment management. The proposed system aims to predict NAC outcomes across three categories: pathological complete response (CR), partial response (PR), and stable disease (SD), by analyzing multimodal magnetic resonance images with clinical and molecular subtype markers. To ensure the comprehensiveness of our system design, texture radiomics were extracted from T1, T2, and STIR MRI modalities, along with functional radiomics from diffusion-weighted MRI at various b-values. The main rationale behind employing multiple b-values in collecting DW-MRI is to effectively capture the complexities of blood diffusion within the tumor microstructure. The proposed system comprises several key steps: (i) extracting texture and functional radiomics from T1, T2, STIR MRI, and DW-MRI data; (ii) identifying the most significant radiomics correlated with NAC treatment using a genetic algorithm; (iii) initially predicting the PR from alternative treatment responses utilizing the extracted textures and functional radiomics; and (iv) subsequently integrating clinical and molecular subtype markers with imaging radiomics to differentiate between CR and SD. Our proposed system is trained and validated through the utilization of a leave-one-subject-out (LOSO) cross-validation approach on various MRI scans from 109 subjects, of whom 27 had complete responses, 54 had partial responses, and 28 had no responses. The performance of the proposed system was assessed through the utilization of Cohen’s Kappa and accuracy metrics, achieving 81.31% and 88.07%, respectively. Our various experiments showed that integrating clinical and molecular subtype markers with radiomics highlights the proposed system’s efficiency in evaluating the tumor’s response to NAC efficiently, outperforming predictions based solely on individual radiomics.INDEX TERMS Breast cancer, neoadjuvant chemotherapy, MRI, DW-MRI, radiomics, tumor clinical markers, machine learning, treatment response prediction.

Computer Science,Medicine
Deep learning of quantitative ultrasound multi-parametric images at pre-treatment to predict breast cancer response to chemotherapy

Hamidreza Taleghamar,Seyed Ali Jalalifar,Gregory J. Czarnota,Ali Sadeghi-Naini

DOI: https://doi.org/10.1038/s41598-022-06100-2

IF: 4.6

2022-02-10

Scientific Reports

Abstract:Abstract In this study, a novel deep learning-based methodology was investigated to predict breast cancer response to neo-adjuvant chemotherapy (NAC) using the quantitative ultrasound (QUS) multi-parametric imaging at pre-treatment. QUS multi-parametric images of breast tumors were generated using the data acquired from 181 patients diagnosed with locally advanced breast cancer and planned for NAC followed by surgery. The ground truth response to NAC was identified for each patient after the surgery using the standard clinical and pathological criteria. Two deep convolutional neural network (DCNN) architectures including the residual network and residual attention network (RAN) were explored for extracting optimal feature maps from the parametric images, with a fully connected network for response prediction. In different experiments, the features maps were derived from the tumor core only, as well as the core and its margin. Evaluation results on an independent test set demonstrate that the developed model with the RAN architecture to extract feature maps from the expanded parametric images of the tumor core and margin had the best performance in response prediction with an accuracy of 88% and an area under the receiver operating characteristic curve of 0.86. Ten-year survival analyses indicate statistically significant differences between the survival of the responders and non-responders identified based on the model prediction at pre-treatment and the standard criteria at post-treatment. The results of this study demonstrate the promising capability of DCNNs with attention mechanisms in predicting breast cancer response to NAC prior to the start of treatment using QUS multi-parametric images.

multidisciplinary sciences
Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning (DL) Method

Yu-Hong Qu,Hai-Tao Zhu,Kun Cao,Xiao-Ting Li,Meng Ye,Ying-Shi Sun

DOI: https://doi.org/10.1111/1759-7714.13309

IF: 3.223

2020-01-01

Thoracic Cancer

Abstract:Abstract Background The aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer. Methods A total of 302 breast cancer patients in this retrospective study were randomly divided into a training set (n = 244) and a validation set (n = 58). Tumor regions were manually delineated on each slice by two expert radiologists on enhanced T1‐weighted images. Pathological results were used as ground truth. Deep learning network contained five repetitions of convolution and max‐pooling layers and ended with three dense layers. The pre‐NAC model and post‐NAC model inputted six phases of pre‐NAC and post‐NAC images, respectively. The combined model used 12 channels from six phases of pre‐NAC and six phases of post‐NAC images. All models above included three indexes of molecular type as one additional input channel. Results The training set contained 137 non‐pCR and 107 pCR participants. The validation set contained 33 non‐pCR and 25 pCR participants. The area under the receiver operating characteristic (ROC) curve (AUC) of three models was 0.553 for pre‐NAC, 0.968 for post‐NAC and 0.970 for the combined data, respectively. A significant difference was found in AUC between using pre‐NAC data alone and combined data (P < 0.001). The positive predictive value of the combined model was greater than that of the post‐NAC model (100% vs. 82.8%, P = 0.033). Conclusion This study established a deep learning model to predict PCR status after neoadjuvant therapy by combining pre‐NAC and post‐NAC MRI data. The model performed better than using pre‐NAC data only, and also performed better than using post‐NAC data only. Key points Significant findings of the study. It achieved an AUC of 0.968 for pCR prediction. It showed a significantly greater AUC than using pre‐NAC data only. What this study adds This study established a deep learning model to predict PCR status after neoadjuvant therapy by combining pre‐NAC and post‐NAC MRI data.
Time‐Series MR Images Identifying Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning Approach

Jialing Liu,Xu Li,Gang Wang,Weixiong Zeng,Hui Zeng,Chanjuan Wen,Weimin Xu,Zilong He,Genggeng Qin,Weiguo Chen

DOI: https://doi.org/10.1002/jmri.29405

IF: 4.4

2024-06-09

Journal of Magnetic Resonance Imaging

Abstract:Background Pathological complete response (pCR) is an essential criterion for adjusting follow‐up treatment plans for patients with breast cancer (BC). The value of the visual geometry group and long short‐term memory (VGG‐LSTM) network using time‐series dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) for pCR identification in BC is unclear. Purpose To identify pCR to neoadjuvant chemotherapy (NAC) using deep learning (DL) models based on the VGG‐LSTM network. Study Type Retrospective. Population Center A: 235 patients (47.7 ± 10.0 years) were divided 7:3 into training (n = 164) and validation set (n = 71). Center B: 150 patients (48.5 ± 10.4 years) were used as test set. Field Strength/Sequence 3‐T, T2‐weighted spin‐echo sequence imaging, and gradient echo DCE sequence imaging. Assessment Patients underwent MRI examinations at three sequential time points: pretreatment, after three cycles of treatment, and prior to surgery, with tumor regions of interest manually delineated. Histopathology was the gold standard. We used VGG‐LSTM network to establish seven DL models using time‐series DCE‐MR images: pre‐NAC images (t0 model), early NAC images (t1 model), post‐NAC images (t2 model), pre‐NAC and early NAC images (t0 + t1 model), pre‐NAC and post‐NAC images (t0 + t2 model), pre‐NAC, early NAC and post‐NAC images (t0 + t1 + t2 model), and the optimal model combined with the clinical features and imaging features (combined model). The models were trained and optimized on the training and validation set, and tested on the test set. Statistical Tests The DeLong, Student's t‐test, Mann–Whitney U, Chi‐squared, Fisher's exact, Hosmer–Lemeshow tests, decision curve analysis, and receiver operating characteristics analysis were performed. P

radiology, nuclear medicine & medical imaging
Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

Sunghoon Joo,Eun Sook Ko,Soonhwan Kwon,Eunjoo Jeon,Hyungsik Jung,Ji-Yeon Kim,Myung Jin Chung,Young-Hyuck Im

DOI: https://doi.org/10.1038/s41598-021-98408-8

IF: 4.6

2021-09-22

Scientific Reports

Abstract:Abstract The achievement of the pathologic complete response (pCR) has been considered a metric for the success of neoadjuvant chemotherapy (NAC) and a powerful surrogate indicator of the risk of recurrence and long-term survival. This study aimed to develop a multimodal deep learning model that combined clinical information and pretreatment MR images for predicting pCR to NAC in patients with breast cancer. The retrospective study cohort consisted of 536 patients with invasive breast cancer who underwent pre-operative NAC. We developed a deep learning model to fuse high-dimensional MR image features and the clinical information for the pretreatment prediction of pCR to NAC in breast cancer. The proposed deep learning model trained on all datasets as clinical information, T1-weighted subtraction images, and T2-weighted images shows better performance with area under the curve (AUC) of 0.888 as compared to the model using only clinical information (AUC = 0.827, P < 0.05). Our results demonstrate that the multimodal fusion approach using deep learning with both clinical information and MR images achieve higher prediction performance compared to the deep learning model without the fusion approach. Deep learning could integrate pretreatment MR images with clinical information to improve pCR prediction performance.

multidisciplinary sciences
Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment

Jionghui Gu,Xian Zhong,Chengyu Fang,Wenjing Lou,Peifen Fu,Henry C Woodruff,Baohua Wang,Tianan Jiang,Philippe Lambin

DOI: https://doi.org/10.1093/oncolo/oyad227

2023-09-05

The Oncologist

Abstract:Abstract Background Not only should resistance to neoadjuvant chemotherapy (NAC) be considered in patients with breast cancer but also the possibility of achieving a pathologic complete response (PCR) after NAC. Our study aims to develop 2 multimodal ultrasound deep learning (DL) models to noninvasively predict resistance and PCR to NAC before treatment. Methods From January 2017 to July 2022, a total of 170 patients with breast cancer were prospectively enrolled. All patients underwent multimodal ultrasound examination (grayscale 2D ultrasound and ultrasound elastography) before NAC. We combined clinicopathological information to develop 2 DL models, DL_Clinical_resistance and DL_Clinical_PCR, for predicting resistance and PCR to NAC, respectively. In addition, these 2 models were combined to stratify the prediction of response to NAC. Results In the test cohort, DL_Clinical_resistance had an AUC of 0.911 (95%CI, 0.814-0.979) with a sensitivity of 0.905 (95%CI, 0.765-1.000) and an NPV of 0.882 (95%CI, 0.708-1.000). Meanwhile, DL_Clinical_PCR achieved an AUC of 0.880 (95%CI, 0.751-0.973) and sensitivity and NPV of 0.875 (95%CI, 0.688-1.000) and 0.895 (95%CI, 0.739-1.000), respectively. By combining DL_Clinical_resistance and DL_Clinical_PCR, 37.1% of patients with resistance and 25.7% of patients with PCR were successfully identified by the combined model, suggesting that these patients could benefit by an early change of treatment strategy or by implementing an organ preservation strategy after NAC. Conclusions The proposed DL_Clinical_resistance and DL_Clinical_PCR models and combined strategy have the potential to predict resistance and PCR to NAC before treatment and allow stratified prediction of NAC response.

oncology
Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients

Hongyi Dammu,Thomas Ren,Tim Q. Duong

DOI: https://doi.org/10.1371/journal.pone.0280148

IF: 3.7

2023-01-07

PLoS ONE

Abstract:The goal of this study was to employ novel deep-learning convolutional-neural-network (CNN) to predict pathological complete response (PCR), residual cancer burden (RCB), and progression-free survival (PFS) in breast cancer patients treated with neoadjuvant chemotherapy using longitudinal multiparametric MRI, demographics, and molecular subtypes as inputs. In the I-SPY-1 TRIAL, 155 patients with stage 2 or 3 breast cancer with breast tumors underwent neoadjuvant chemotherapy met the inclusion/exclusion criteria. The inputs were dynamic-contrast-enhanced (DCE) MRI, and T2- weighted MRI as three-dimensional whole-images without the tumor segmentation, as well as molecular subtypes and demographics. The outcomes were PCR, RCB, and PFS. Three ("Integrated", "Stack" and "Concatenation") CNN were evaluated using receiver-operating characteristics and mean absolute errors. The Integrated approach outperformed the "Stack" or "Concatenation" CNN. Inclusion of both MRI and non-MRI data outperformed either alone. The combined pre- and post-neoadjuvant chemotherapy data outperformed either alone. Using the best model and data combination, PCR prediction yielded an accuracy of 0.81±0.03 and AUC of 0.83±0.03; RCB prediction yielded an accuracy of 0.80±0.02 and Cohen's κ of 0.73±0.03; PFS prediction yielded a mean absolute error of 24.6±0.7 months (survival ranged from 6.6 to 127.5 months). Deep learning using longitudinal multiparametric MRI, demographics, and molecular subtypes accurately predicts PCR, RCB, and PFS in breast cancer patients. This approach may prove useful for treatment selection, planning, execution, and mid-treatment adjustment.

multidisciplinary sciences
The neuroleptic malignant syndrome--a review.

W. Gibb,A. Lees

DOI: https://doi.org/10.1093/OXFORDJOURNALS.QJMED.A067888

1985-08-01

Abstract:The neuroleptic malignant syndrome (NMS) is an uncommon disorder characterised by muscular stiffness and hyperthermia. It is caused by the administration of neuroleptics or by the acute withdrawal of levodopa therapy in idiopathic Parkinson's disease. An identical syndrome may be seen rarely in untreated catatonic schizophrenia. Shock, respiratory failure and myoglobinuria occur sometimes with serious consequences. Treatment should include active cooling measures and the administration of dopamine agonists. Dantrolene may also be of benefit in severe cases.
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer

Soo-Yeon Kim,Jinsu Lee,Nariya Cho,Young-Gon Kim

DOI: https://doi.org/10.1038/s41598-024-74276-w

IF: 4.6

2024-10-06

Scientific Reports

Abstract:Distinguishing between pathologic complete response and residual cancer after neoadjuvant chemotherapy (NAC) is crucial for treatment decisions, but the current imaging methods face challenges. To address this, we developed deep-learning models using post-NAC dynamic contrast-enhanced MRI and clinical data. A total of 852 women with human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer were randomly divided into a training set ( n = 724) and a validation set ( n = 128). A 3D convolutional neural network model was trained on the training set and validated independently. The main models were developed using cropped MRI images, but models using uncropped whole images were also explored. The delayed-phase model demonstrated superior performance compared to the early-phase model (area under the receiver operating characteristic curve [AUC] = 0.74 vs. 0.69, P = 0.013) and the combined model integrating multiple dynamic phases and clinical data (AUC = 0.74 vs. 0.70, P = 0.022). Deep-learning models using uncropped whole images exhibited inferior performance, with AUCs ranging from 0.45 to 0.54. Further refinement and external validation are necessary for enhanced accuracy.

multidisciplinary sciences
Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

Yunsong Peng,Ziliang Cheng,Chang Gong,Chushan Zheng,Xiang Zhang,Zhuo Wu,Yaping Yang,Xiaodong Yang,Jian Zheng,Jun Shen

DOI: https://doi.org/10.3389/fonc.2022.846775

IF: 4.7

2022-03-10

Frontiers in Oncology

Abstract:Purpose To compare the performances of deep learning (DL) to radiomics analysis (RA) in predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) based on pretreatment dynamic contrast-enhanced MRI (DCE-MRI) in breast cancer. Materials and Methods This retrospective study included 356 breast cancer patients who underwent DCE-MRI before NAC and underwent surgery after NAC. Image features and kinetic parameters of tumors were derived from DCE-MRI. Molecular information was assessed based on immunohistochemistry results. The image-based RA and DL models were constructed by adding kinetic parameters or molecular information to image-only linear discriminant analysis (LDA) and convolutional neural network (CNN) models. The predictive performances of developed models were assessed by receiver operating characteristic (ROC) curve analysis and compared with the DeLong method. Results The overall pCR rate was 23.3% (83/356). The area under the ROC (AUROC) of the image-kinetic-molecular RA model was 0.781 [95% confidence interval (CI): 0.735, 0.828], which was higher than that of the image-kinetic RA model (0.629, 95% CI: 0.595, 0.663; P < 0.001) and comparable to that of the image-molecular RA model (0.755, 95% CI: 0.708, 0.802; P = 0.133). The AUROC of the image-kinetic-molecular DL model was 0.83 (95% CI: 0.816, 0.847), which was higher than that of the image-kinetic and image-molecular DL models (0.707, 95% CI: 0.654, 0.761; 0.79, 95% CI: 0.768, 0.812; P < 0.001) and higher than that of the image-kinetic-molecular RA model (0.778, 95% CI: 0.735, 0.828; P < 0.001). Conclusions The pretreatment DCE-MRI-based DL model is superior to the RA model in predicting pCR to NAC in breast cancer patients. The image-kinetic-molecular DL model has the best prediction performance.

oncology
A transformer model guided by histopathological image information for DCE-MRI-based prediction of response to neoadjuvant chemotherapy in breast cancer

Lihua Li,Yuanlin Chen,Xinxin Pan,Xinquan Xiao,Zhou Yu,M. Fan

DOI: https://doi.org/10.1117/12.3006656

2024-04-02

Abstract:Pathologic diagnosis is the "gold standard" for diagnosing breast cancer and is increasingly used to assess the response to Neoadjuvant Chemotherapy (NACT). Despite its high accuracy and sensitivity, pathology is invasive and requires biopsy of the patient's breast tissue. Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) is the standard of care in breast cancer management and is critical for noninvasive prediction of pathological response to NACT. To this end, we propose a transformer model based on DCE-MRI that is guided by histopathological image data to predict responses to NACT. A cross-attention mechanism was developed to facilitate information interaction between histopathological images and DCE-MRI. Specifically, we designed a modality information transfer module to synthesize histopathological image features from DCE-MRI features. During the training stage, we propose to stochastically use synthesize histopathological image features rather than the real features as network inputs. This strategy enables us to predict the response to NACT by using DCE-MRI alone, regardless of the availability of histopathological images. In this study, 239 patients with paired DCE-MRI and histologic images were included; 32 patients (13.4%) achieved a pathological Complete Response (pCR), while 207 patients (13.4%) had nonpCR. A total of 146 samples were used as the training set, and 93 samples were used as the testing set. The experimental results showed that the proposed histopathological information-guided model using DCE-MRI and histopathological images had a greater predictive performance (AUC=0.824) than either the traditional DCE-MRI (AUC=0.687) or histopathological image-based model (AUC=0.765) in predicting the response to NACT in patients with breast cancer.

Engineering,Medicine
Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer

Yuting Li,Yaheng Fan,Dinghua Xu,Yan Li,Zhangnan Zhong,Haoyu Pan,Bingsheng Huang,Xiaotong Xie,Yang Yang,Bihua Liu

DOI: https://doi.org/10.3389/fonc.2022.1041142

IF: 4.7

2023-01-06

Frontiers in Oncology

Abstract:Objective: The aim of this study was to develop and validate a deep learning-based radiomic (DLR) model combined with clinical characteristics for predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer. For early prediction of pCR, the DLR model was based on pre-treatment and early treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) data. Materials and methods: This retrospective study included 95 women (mean age, 48.1 years; range, 29–77 years) who underwent DCE-MRI before (pre-treatment) and after two or three cycles of NAC (early treatment) from 2018 to 2021. The patients in this study were randomly divided into a training cohort (n=67) and a validation cohort (n=28) at a ratio of 7:3. Deep learning and handcrafted features were extracted from pre- and early treatment DCE-MRI contoured lesions. These features contribute to the construction of radiomic signature RS1 and RS2 representing information from different periods. Mutual information and least absolute shrinkage and selection operator regression were used for feature selection. A combined model was then developed based on the DCE-MRI features and clinical characteristics. The performance of the models was assessed using the area under the receiver operating characteristic curve (AUC) and compared using the DeLong test. Results: The overall pCR rate was 25.3% (24/95). One radiomic feature and three deep learning features in RS1, five radiomic features and 11 deep learning features in RS2, and five clinical characteristics remained in the feature selection. The performance of the DLR model combining pre- and early treatment information (AUC=0.900) was better than that of RS1 (AUC=0.644, P=0.068) and slightly higher that of RS2 (AUC=0.888, P=0.604) in the validation cohort. The combined model including pre- and early treatment information and clinical characteristics showed the best ability with an AUC of 0.925 in the validation cohort. Conclusion: The combined model integrating pre-treatment, early treatment DCE-MRI data, and clinical characteristics showed good performance in predicting pCR to NAC in patients with breast cancer. Early treatment DCE-MRI and clinical characteristics may play an important role in evaluating the outcomes of NAC by predicting pCR.

oncology
Automated Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy from DWI Data

Shir Nitzan,Maya Gilad,Moti Freiman

2024-04-08

Abstract:Effective surgical planning for breast cancer hinges on accurately predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). Diffusion-weighted MRI (DWI) and machine learning offer a non-invasive approach for early pCR assessment. However, most machine-learning models require manual tumor segmentation, a cumbersome and error-prone task. We propose a deep learning model employing "Size-Adaptive Lesion Weighting" for automatic DWI tumor segmentation to enhance pCR prediction accuracy. Despite histopathological changes during NAC complicating DWI image segmentation, our model demonstrates robust performance. Utilizing the BMMR2 challenge dataset, it matches human experts in pCR prediction pre-NAC with an area under the curve (AUC) of 0.76 vs. 0.796, and surpasses standard automated methods mid-NAC, with an AUC of 0.729 vs. 0.654 and 0.576. Our approach represents a significant advancement in automating breast cancer treatment planning, enabling more reliable pCR predictions without manual segmentation.

Computer Vision and Pattern Recognition,Artificial Intelligence
Prediction of response to neoadjuvant chemotherapy in breast cancer with recurrent neural networks and raw ultrasound signals

Michał Byra,Katarzyna Dobruch-Sobczak,Hanna Piotrzkowska-Wroblewska,Ziemowit Klimonda,Jerzy Litniewski

DOI: https://doi.org/10.1088/1361-6560/ac8c82

IF: 3.5

2022-08-26

Physics in Medicine and Biology

Abstract:Objective: Prediction of the response to neoadjuvant chemotherapy (NAC) in breast cancer is important for patient outcomes. In this work, we propose a deep learning based approach to NAC response prediction in ultrasound (US) imaging. Approach: We develop recurrent neural networks that can process serial US imaging data to predict chemotherapy outcomes. We present models that can process either raw radio-frequency (RF) US data or regular US images. The proposed approach is evaluated based on 204 sequences of US data from 51 breast cancers. Each sequence included US data collected before the chemotherapy and after each subsequent dose, up to the 4th course. We investigate three pre-trained convolutional neural networks (CNNs) as back-bone feature extractors for the recurrent network. The CNNs were pre-trained using raw US RF data, US images and RGB images from the ImageNet dataset. The first two networks were developed using US data collected from malignant and benign breast masses. Main results: For the pre-treatment data, the better performing network, with back-bone CNN pre-trained on US images, achieved area under the receiver operating curve (AUC) of 0.81 (±0.04). Performance of the recurrent networks improved with each course of the chemotherapy. For the 4th course, the better performing model, based on the CNN pre-trained with RGB images, achieved AUC value of 0.93 (±0.03). Statistical analysis based on the DeLong test presented that there were no significant differences in AUC values between the pre-trained networks at each stage of the chemotherapy (p-values>0.05). Significance: Our study demonstrates the feasibility of using recurrent neural networks for the NAC response prediction in breast cancer US.

engineering, biomedical,radiology, nuclear medicine & medical imaging
Multimodal Spatiotemporal Deep Learning Framework to Predict Response of Breast Cancer to Neoadjuvant Systemic Therapy

Monu Verma,Leila Abdelrahman,Fernando Collado-Mesa,Mohamed Abdel-Mottaleb

DOI: https://doi.org/10.3390/diagnostics13132251

IF: 3.6

2023-07-05

Diagnostics

Abstract:Current approaches to breast cancer therapy include neoadjuvant systemic therapy (NST). The efficacy of NST is measured by pathologic complete response (pCR). A patient who attains pCR has significantly enhanced disease-free survival progress. The accurate prediction of pCR in response to a given treatment regimen could increase the likelihood of achieving pCR and prevent toxicities caused by treatments that are not effective. Th early prediction of response to NST can increase the likelihood of survival and help with decisions regarding breast-conserving surgery. An automated NST prediction framework that is able to precisely predict which patient undergoing NST will achieve a pathological complete response (pCR) at an early stage of treatment is needed. Here, we propose an end-to-end efficient multimodal spatiotemporal deep learning framework (deep-NST) framework to predict the outcome of NST prior or at an early stage of treatment. The deep-NST model incorporates imaging data captured at different timestamps of NST regimens, a tumor's molecular data, and a patient's demographic data. The efficacy of the proposed work is validated on the publicly available ISPY-1 dataset, in terms of accuracy, area under the curve (AUC), and computational complexity. In addition, seven ablation experiments were carried out to evaluate the impact of each design module in the proposed work. The experimental results show that the proposed framework performs significantly better than other recent methods.

medicine, general & internal

Changes in the nutrient quality of meat in an obesity context.

Assessing Breast Cancer Volume Alterations Post-Neoadjuvant Chemotherapy Through DenseNet-201 Deep Learning Analysis on DCE-MRI

Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset

Deep learning-based prediction of response to HER2-targeted neoadjuvant chemotherapy from pre-treatment dynamic breast MRI: A multi-institutional validation study

Explainable 3D CNN based on baseline breast DCE-MRI to give an early prediction of pathological complete response to neoadjuvant chemotherapy

Deep Learning Model Based on Dual-Modal Ultrasound and Molecular Data for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer

A Novel Machine Learning Approach for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: Integration of Multimodal Radiomics With Clinical and Molecular Subtype Markers

Deep learning of quantitative ultrasound multi-parametric images at pre-treatment to predict breast cancer response to chemotherapy

Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning (DL) Method

Time‐Series MR Images Identifying Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning Approach

Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

Deep Learning of Multimodal Ultrasound: Stratifying the Response to Neoadjuvant Chemotherapy in Breast Cancer Before Treatment

Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients

The neuroleptic malignant syndrome--a review.

Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer

Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

A transformer model guided by histopathological image information for DCE-MRI-based prediction of response to neoadjuvant chemotherapy in breast cancer

Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer

Automated Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy from DWI Data

Prediction of response to neoadjuvant chemotherapy in breast cancer with recurrent neural networks and raw ultrasound signals

Multimodal Spatiotemporal Deep Learning Framework to Predict Response of Breast Cancer to Neoadjuvant Systemic Therapy